The Relationship Between Average Daily Dose, Medication Adherence, and Health-Care Costs among Diabetic Peripheral Neuropathic Pain Patients Initiated on Duloxetine Therapy

Pain Practice

Volumn 10, Issue 6, 2010, Pages 530-539

  Chen, Shih Yin ^a   Wu, Ning ^a   Boulanger, Luke ^a   Fraser, Kimberly A ^a   Zhao, Yang ^b  

^a Formerly Abt Bio Pharma Solutions Inc   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Average daily dose; Diabetic neuropathy; Duloxetine; Health care costs; Medication adherence; Painful; Pharmacologic actions

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; CODEINE; CYCLOOXYGENASE 2 INHIBITOR; DEXTROPROPOXYPHENE; DULOXETINE; GABAPENTIN; HYDROCODONE; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; PREGABALIN; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DIABETIC PERIPHERAL NEUROPATHIC PAIN; DRUG DOSE; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; NEUROPATHIC PAIN; PATIENT COMPLIANCE; PRESCRIPTION; RETROSPECTIVE STUDY; TREATMENT DURATION;

EID: 78049466737     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2010.00372.x     Document Type: Article

References (36)

1. Argoff CE, Cole BE, Fishbain DA, Irving GA. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clin Proc. 2006;81:S3-S11.
2. Boulton AJ. Management of diabetic peripheral neuropathy. Clin Diabetes. 2005;23:9-15.
3. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care. 2004;27:1458-1486.
4. Boulton AJ, Vinik AI, Arezzo JC, et al. American Diabetes Association: diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28:956-962.
5. Daousi C, MacFarlane IA, Woodward A, Nurmikkot TJ, Bundred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med. 2004;21:976-982.
6. Hall GC, Carroll D, Parry D, McQuay HJ. Epidemiology and treatment of neuropathic pain: the UK primary care perspective. Pain. 2006;122:156-162.
7. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract. 2000;47:123-128.
8. Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain. Mayo Clin Proc. 2006;81:S12-S25.
9. Gore M, Brandenburg NA, Dukes E, Hoffman DL, Tai KS, Stacey B. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage. 2005;30:374-385.
10. Benbow SJ, Wallymahmed ME, MacFarlane IA. Diabetic peripheral neuropathy and quality of life. Q J Med. 1998;91:733-737.
11. Gore M, Brandenburg NA, Hoffman DL, Tai KS, Stacey B. Burden of illness in painful diabetic peripheral neuropathy: the patients' perspectives. J Pain. 2006;7:892-900.
12. Candrilli SD, Davis KL, Kan HJ, Lucero MA, Rousculp MD. Prevalence and the associated burden of illness of symptoms of diabetic peripheral neuropathy and diabetic retinopathy. J Diabetes Complications. 2007;21:306-314.
13. Cole BE. Diabetic peripheral neuropathic pain: recognition and management. Pain Med. 2007;8:S27-S32.
14. Le TK, Able SL, Lage MJ. Resource use among patients with diabetes, diabetic neuropathy, or diabetes with depression. Cost Eff Resour Alloc. 2006;4:18.
15. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of DPN in the US. Diabetes Care. 2003;26:1790-1795.
16. Stewart WF, Ricci JA, Chee E, Hirsch AG, Brandenburg NA. Lost productive time and costs due to diabetes and diabetic neuropathic pain in the US workforce. J Occup Environ Med. 2007;49:672-679.
17. Jude EB, Jacob K. Managing painful neuropathy in diabetes. Pol Arch Med Wewn. 2008;118:260-261.
18. Chong MS, Hester J. Diabetic painful neuropathy: current and future treatment options. Drugs. 2007;67:569-585.
19. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.
20. American Diabetes Association. Standards of Medical Care in Diabetes-2008. Diabetes Care. 2008;31:S12-S54.
21. American Pain Society of Educators and University of Wisconsin School of Medicine and Public Health. Diabetic peripheral neuropathic pain. Consensus guidelines for treatment. J Fam Pract. 2006;Suppl:3-19.
22. Boulanger L, Zhao Y, Foster TS, Fraser K, Bledsoe SL, Russell MW. Impact of comorbid depression or anxiety on patterns of treatment and economic outcomes among patients with diabetic peripheral neuropathic pain. Curr Med Res Opin. 2009;25:1763-1773.
23. Wu N, Chen S, Boulanger L, Fraser K, Bledsoe SL, Zhao Y. Duloxetine compliance and its association with healthcare costs among patients with diabetic peripheral neuropathic pain. J Med Econ. 2009;12:192-202.
24. Cymbalta®[Package Insert]. Indianapolis, IN: Eli Lilly and Company; 2004.
25. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM adminstrative databases. J Clin Epidemiol. 1992;45:613-619.
26. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105-116.
27. Bureau of Labor Statistics. Consumer Price Index. Washington, DC: Bureau of Labor Statistics; 2008.
28. McCullagh P, Nelder JA. Generalized Linear Models. 2nd ed. London: Chapman and Hall; 1989.
29. Afifi AA, Kotlerman JB, Ettner SL, Cowan M. Methods for improving regression analysis for skewed continuous or count responses. Annu Rev Public Health. 2007;28:95-111.
30. Efron B, Tibhirani R. An Introduction to the Bootstrap. New York: Chapman and Hall; 1993.
31. Boulanger L, Zhao Y, Bao Y, Russell MW. A retrospective study on the impact of comoribid depression or anxiety on healthcare resource use and costs among diabetic neuropathy patients. BMC Health Serv Res. 2009;9:111.
32. Chaturvedi N. The burden of diabetes and its complications: trends and implications for intervention. Diabetes Res Clin Pract. 2007;76:S3-12.
33. Boulton AJ. Treatment of symptomatic diabetic neuropathy. Diabetes Metab Res Rev. 2003;19:516-521.
34. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.
35. Currie CJ, Poole CD, Woehl A, et al. The financial costs of healthcare treatment for people with Type 1 or Type 2 diabetes in the UK with particular reference to differing severity of peripheral neuropathy. Diabet Med. 2007;24:187-194.
36. Currie CJ, Poole CD, Woehl A, et al. The health-related utility and health-related quality of life of hospital-treated subjects with type 1 or type 2 diabetes with particular reference to differing severity of peripheral neuropathy. Diabetologia. 2006;49:2272-2280.